[(2R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: [(2R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
• 化学式: C₉H₁₄N₂O₁₂P₂
• 分子量: 404.16
• InChiKey: XCCTYIAWTASOJW-AYZDMWBASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.7
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  212
• 氢给体数：
  6
• 氢受体数：
  12

文献信息

• HIGH-PURITY STEVIOL GLYCOSIDES
  申请人：PureCircle SDN BHD

  公开号：EP4012041A1

  公开（公告）日：2022-06-15

  In the present invention methods of preparing highly purified steviol glycosides, particularly rebaudiosides A, D and X are described. The method includes expression of UDP-glucosyltransferases from Stevia rebaudiana Bertoni, which are capable converting certain steviol glycosides to rebaudiosides A, D and X. The highly purified rebaudiosides A, D and X, are useful as non-caloric sweetener in edible and chewable compositions such as any beverages, confectioneries, bakery products, cookies, and chewing gums.

  本发明描述了制备高纯度甜菊醇苷，特别是甜菊糖苷 A、D 和 X 的方法。该方法包括表达来自 Stevia rebaudiana Bertoni 的 UDP-葡萄糖基转移酶，该酶能够将某些甜菊糖苷转化为甜菊糖苷 A、D 和 X。高度纯化的甜菊糖苷 A、D 和 X 可用作可食用和可咀嚼成分中的无热量甜味剂，如任何饮料、糖果、烘焙食品、饼干和口香糖。
• Triazole derivatives as P2Y14 receptor antagonists
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10683277B2

  公开（公告）日：2020-06-16

  Described are compounds, which are antagonists of the P2Y14 receptor, for example, a compound of formula (I) in which ring A, R1, R2, R3, and n are as described herein. Also provided are dendron conjugates comprising the compounds, and methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P214 receptor activity in a cell.

  所述化合物是 P2Y14 受体的拮抗剂，例如，式 (I) 化合物，其中环 A、R1、R2、R3 和 n 如本文所述。还提供了包含这些化合物的树枝膦结合物，以及使用这些化合物的方法，包括治疗疾病的方法，如炎症、糖尿病、胰岛素抵抗、高血糖、血脂紊乱、肥胖、与代谢综合征相关的疾病和哮喘，以及拮抗细胞中 P214 受体活性的方法。
• PEGYLATED FACTOR VII GLYCOFORMS
  申请人：Novo Nordisk Health Care AG

  公开号：EP1517710B1

  公开（公告）日：2011-03-30
• PROCESS FOR PRODUCING A HIGH-PURITY STEVIOL GLYCOSIDE
  申请人：PureCircle SDN BHD

  公开号：EP2852296B1

  公开（公告）日：2021-12-15
• TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：EP3353161B1

  公开（公告）日：2021-07-21